Last reviewed · How we verify
Survanta (BERACTANT)
Survanta (beractant) is a surfactant medication originally developed by AbbVie and currently owned by the same company. It is a small molecule drug that works by reducing surface tension in the lungs, making it easier for newborns to breathe. Survanta is FDA-approved to treat respiratory distress syndrome in newborns and has been on the market since 1991. The commercial status of Survanta is patented, and it is not yet available as a generic medication. Key safety considerations include proper dosing and administration to minimize the risk of complications.
At a glance
| Generic name | BERACTANT |
|---|---|
| Sponsor | AbbVie |
| Drug class | Surfactant [EPC] |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Respiratory distress syndrome in the newborn
Common side effects
- Pulmonary haemorrhage
- Neurodevelopmental disorder
Key clinical trials
- Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia (NA)
- Less Invasive Beractant Administration in Preterm Infants (NA)
- Aerosolized Surfactant in Neonatal RDS (PHASE1,PHASE2)
- Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations (PHASE4)
- Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome (PHASE2,PHASE3)
- Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound (NA)
- MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants (PHASE2)
- The Effect of Surfactant Administration on Cerebral Oxygenation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Survanta CI brief — competitive landscape report
- Survanta updates RSS · CI watch RSS
- AbbVie portfolio CI